CP and DA participants randomized to the MMA+ condition will demonstrate significant reductions in mood symptoms (state depression and anxiety) after the MM task compared with CP and DA participants randomized to the MMA− condition, reflecting the potential for MMA+ to facilitate the emotion regulation effects of MM for clinical populations. The gene discussed is CP; the disease is depressive symptom measurement.